BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  CIS  bio  international  submitted  on  21  November  1996  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Quadramet, through the centralised procedure. After agreement by the CPMP on 16 October 1996, this 
medicinal  product  is  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EC)  2309/93  of  22 
July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr D B Jefferys 
Co-Rapporteur:  Dr G Jensen 
Licensing status 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
3. 
• 
Steps taken for the assessment of the product 
The procedure started on 19 December 1996 
The Rapporteur's first assessment report was circulated to all CPMP Members on 27 February 
1997 
The  Co-rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 
28 February 1997 
During the meeting on 15 April 1997 the CPMP agreed on the consolidated list of questions to 
be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the  company  on 
17 April 1997. 
The company submitted the responses to the consolidated list of questions on 25 July 1997. 
The Rapporteur circulated the joint assessment report on the company’s responses to the list of 
questions to all CPMP Members on 28 August 1997. 
Following discussion of the applicant’s responses at the September 1997 meeting of CPMP the 
Rapporteur  requested  further  information  from  the  applicant  on  29  September  1997,  and  this 
was provided on 2 October 1997. 
The Rapporteur circulated a revised SPC, PIL on 13 October 1997. 
During the meeting on 20-22 October 1997 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to CIS bio international on 22 October 1997. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission which adopted the corresponding Decisions on 5 February 1998. 
Steps taken after granting the Marketing authorisation 
On  25  November  1998  three  Type  I  variation  procedures  were  started  to  introduce  minor 
changes to the manufacture of the active substance (I/01) and to the finished product (I/02-03). 
The proposed variations were accepted on 23 December 1998. 
1/1 
   EMEA 2004 
 
 
 
 
 
 
 
